ENvizion Medical Valuation
Is ENVM-L undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ENVM-L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ENVM-L's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ENVM-L's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ENVM-L?
Other financial metrics that can be useful for relative valuation.
What is ENVM-L's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$473.11k |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.2x |
Enterprise Value/EBITDA | -0.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ENVM-L's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.9x | ||
SLCL Silver Castle Holdings | 5.5x | n/a | ₪15.9m |
IDNT Identi Healthcare | 2.8x | n/a | ₪28.4m |
BIOV Bio-View | 1.1x | n/a | ₪36.7m |
HUMX Human Xtensions | 2.3x | n/a | ₪11.5m |
ENVM-L ENvizion Medical | 0.6x | n/a | ₪1.8m |
Price-To-Sales vs Peers: ENVM-L is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does ENVM-L's PE Ratio compare vs other companies in the Asian Medical Equipment Industry?
Price-To-Sales vs Industry: ENVM-L is good value based on its Price-To-Sales Ratio (0.6x) compared to the Asian Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is ENVM-L's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ENVM-L's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.